Publications
Publications
- October 2022
- HBS Case Collection
Cost Plus Drugs
By: Alexander MacKay and James Barnett
Abstract
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies. Oshmyansky could focus resources on adding brand-name drugs to its medication portfolio or focus on the company’s ongoing development of a facility to manufacture sterile injectable drugs.
Keywords
Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Health Industry; Pharmaceutical Industry; United States; Texas
Citation
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.